Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q4 2023 Earnings Call Transcript
Phathom Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0.8, expectations were $-0.92.
Phathom Pharmaceuticals Inc. (PHAT)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Avidity Partners Management David Witzke And Michael Gregory | 1,721,580 | $15,718,025 | +7% | 0.57% |
| 2. | 683 Capital Partners Ari Zweiman | 1,280,000 | $11,686,401 | +17% | 0.95% |
| 3. | Woodline Partners Michael Rockefeller And Karl Kroeker | 1,096,121 | $10,007,585 | +49% | 0.1% |
| 4. | Decheng Capital Min Cui | 850,000 | $7,760,500 | 2.16% | |
| 5. | Newtyn Management Noah Levy And Eugene Dozortsev | 646,760 | $5,904,919 | +30% | 1.15% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $7.80 | 2,500 | Director | 55,000 | 2023-11-08 | Filing | |
| $7.76 | 4,000 | Director | 52,500 | 2023-11-07 | Filing | |
| $8.04 | 1,000 | Director | 48,500 | 2023-11-06 | Filing | |
| $7.55 | 1,000 | Director | 23,500 | 2023-04-10 | Filing | |
| $8.26 | 10,000 | Officer | 99,567 | 2023-04-11 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $11.10 | 3,435 | 95,263 | 2024-04-08 | Filing | ||
| $9.11 | 16,851 | 410,784 | 2024-03-22 | Filing | ||
| $8.10 | 3,703,703 | Large Shareholder | 3,755,583 | 2024-01-24 | Filing | |
| $7.75 | 6,307 | Officer | 98,698 | 2024-01-19 | Filing | |
| $7.24 | 2,127 | Officer | 103,061 | 2023-11-20 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 10,109,279 | $92,297,717 | 4.93% | |
| 2. | 3,760,869 | $34,336,734 | 11.59% | |
| 3. | 3,496,808 | $31,925,857 | 1.53% | |
| 4. | 3,167,653 | $28,920,672 | 0% | |
| 5. | 2,678,891 | $24,458,274 | 0% |
News See All
Hedge Fund and Insider Trading News: Amber Capital UK LLP, Third Point LLC, D.E. Shaw, Odey Asset Management, Alameda Research, North Rock Digital, FedEx Corp (FDX), Domo, Inc. (DOMO), and More
Amber Capital UK LLP founder Joseph Oughourlian denied a news report that claimed he was in talks with several private equity funds to take control of Spanish defense group Indra Sistemas SA.
Hedge Fund and Insider Trading News: Anthony Scaramucci, Nelson Peltz, Bill Ackman, Leon Cooperman, Standard General LP, Comtech Telecomm. Corp. (CMTL), Tilly's, Inc. (TLYS), and More
SkyBridge Capital can buy back the stake it sold to collapsed cryptocurrency exchange FTX but the issue will likely take months to resolve, the investment firm’s founder Anthony Scaramucci told CNBC...
Were Hedge Funds Right About Phathom Pharmaceuticals, Inc. (PHAT)?
Many prominent investors, including Warren Buffett, David Tepper and Stan Druckenmiller, have been cautious regarding the current bull market and missed out as the stock market reached another high in...
Here is What Hedge Funds Think About Phathom Pharmaceuticals, Inc. (PHAT)
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW).
Hedge Funds Are Selling Phathom Pharmaceuticals, Inc. (PHAT)
In this article we will check out the progression of hedge fund sentiment towards Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) and determine whether it is a good investment right now.
Billionaire Hedge Funds
